Table 2 Proportion of participants who received antiretroviral prescriptions according to age strata (< 50 vs. ≥ 50 years) in a referral center in Rio de Janeiro, Brazil, 2019 (N = 4547)
|  | Total N = 4547 (%) | < 50 years N = 2932 (%) | ≥ 50 years N = 1615 (%) | P value |
|---|---|---|---|---|
NRTI1 | 4348 (95.6) | 2858 (97.5) | 1490 (92.3) | < 0.001 |
Lamivudine | 4337 (95.4) | 2853 (97.3) | 1484 (91.9) | < 0.001 |
Tenofovir | 3718 (81.8) | 2608 (88.9) | 1110 (68.7) | < 0.001 |
Abacavir | 343 (7.5) | 151 (5.2) | 192 (11.9) | < 0.001 |
Zidovudine | 304 (6.7) | 122 (4.2) | 182 (11.3) | < 0.001 |
NNRTI1 | 1638 (36.0) | 1067 (36.4) | 571 (35.4) | 0.49 |
Efavirenz | 1551 (34.1) | 1031 (35.2) | 520 (32.2) | 0.044 |
Etravirine | 59 (1.3) | 22 (0.8) | 37 (2.3) | < 0.001 |
Nevirapine | 19 (0.4) | 10 (0.3) | 9 (0.6) | 0.28 |
Rilpivirine | 10 (0.2) | 5 (0.2) | 5 (0.3) | 0.34 |
INSTI | 1999 (44.0) | 1302 (44.4) | 697 (43.2) | 0.42 |
Dolutegravir | 1979 (43.5) | 1291 (44.0) | 688 (42.6) | 0.35 |
Raltegravir | 36 (0.8) | 23 (0.8) | 13 (0.8) | 0.94 |
PI | 2023 (44.5) | 1112 (37.9) | 911 (56.4) | < 0.001 |
Ritonavir | 2023 (44.5) | 1112 (37.9) | 911 (56.4) | < 0.001 |
Darunavir | 1180 (26.0) | 616 (21.0) | 564 (34.9) | < 0.001 |
Atazanavir | 909 (20.0) | 529 (18.0) | 380 (23.5) | < 0.001 |
Lopinavir | 12 (0.3) | 6 (0.2) | 6 (0.4) | 0.29 |
Tipranavir | 6 (0.1) | 0 (0) | 6 (0.4) | < 0.001 |
FI | Â | Â | Â | Â |
Enfurvitide | 8 (0.2) | 4 (0.1) | 4 (0.1) | 0.39 |
CCR5 antagonist | Â | Â | Â | Â |
Maraviroc | 40 (0.9) | 13 (0.4) | 27 (1.7) | < 0.001 |